BIOLASE, Inc. Provides Revenue Guidance for First Quarter and Full Year for 2022
March 17, 2022 at 08:05 pm
Share
BIOLASE, Inc. provided revenue guidance for first quarter and Full Year for 2022. The company is anticipating first quarter net revenue to exceed $9.0 million, which would represent growth of at least 11% year over year.
For the year 2022, the Company expects full year net revenue to increase at least 10% from 2021 levels.
BIOLASE, Inc. is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company's systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. It offers two categories of laser system products: Waterlase (all-tissue) systems and diode (soft-tissue) systems. The Company's all-tissue Waterlase dental laser systems consist of its flagship Waterlase iPlus, Waterlase Express, and Waterlase MDX. Its soft tissue diode laser systems consist of the Epic X, Epic Hygiene, Epic Q, and Epic 10 diode lasers that perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and provide temporary pain relief. Epic X, and Epic 10 systems feature its 940 nanometer wavelength with patented pulse technology called ComfortPulse.